Literature DB >> 25183394

Anal cancer: developing an intensity-modulated radiotherapy solution for ACT2 fractionation.

R Muirhead1, R A Adams2, D C Gilbert3, R Glynne-Jones4, M Harrison4, D Sebag-Montefiore5, M A Hawkins6.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25183394     DOI： 10.1016/j.clon.2014.08.001

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN： 0936-6555            Impact factor:   4.126


× No keyword cloud information.
  11 in total

1.  Marginal Gains and Clinical Trials - Improving and Influencing Practice.

Authors:  D C Gilbert; A M Henry; A Choudhury
Journal:  Clin Oncol (R Coll Radiol)       Date:  2022-04-28       Impact factor: 4.925

2.  Target volume motion during anal cancer image guided radiotherapy using cone-beam computed tomography.

Authors:  Corrinne J Brooks; Laurence Bernier; Vibeke N Hansen; Diana M Tait
Journal:  Br J Radiol       Date:  2018-03-06       Impact factor: 3.039

3.  Chemoradiotherapy with Brachytherapy or Electron Therapy Boost for Locally Advanced Squamous Cell Carcinoma of the Anus-Reducing the Colostomy Rate.

Authors:  C Kent; E M Bessell; J H Scholefield; S Chappell; L Marsh; J Mills; I Sayers
Journal:  J Gastrointest Cancer       Date:  2017-03

4.  Initial Results from the Royal College of Radiologists' UK National Audit of Anal Cancer Radiotherapy 2015.

Authors:  R Muirhead; K Drinkwater; S M O'Cathail; R Adams; R Glynne-Jones; M Harrison; M A Hawkins; D Sebag-Montefiore; D C Gilbert
Journal:  Clin Oncol (R Coll Radiol)       Date:  2016-10-31       Impact factor: 4.126

5.  Modeling early haematologic adverse events in conformal and intensity-modulated pelvic radiotherapy in anal cancer.

Authors:  Maxwell Robinson; Ahmed Sabbagh; Rebecca Muirhead; Lisa Durrant; Frank Van den Heuvel; Maria Hawkins
Journal:  Radiother Oncol       Date:  2015-09-22       Impact factor: 6.280

6.  Quantifying target-specific motion in anal cancer patients treated with intensity modulated radiotherapy (IMRT).

Authors:  Lisa Durrant; Maxwell Robinson; Maria A Hawkins; Frank Van den Heuvel; Rebecca Muirhead
Journal:  Radiother Oncol       Date:  2016-08-28       Impact factor: 6.280

Review 7.  Challenges for Quality Assurance of Target Volume Delineation in Clinical Trials.

Authors:  Amy Tien Yee Chang; Li Tee Tan; Simon Duke; Wai-Tong Ng
Journal:  Front Oncol       Date:  2017-09-25       Impact factor: 6.244

8.  Response of FDG avid pelvic bone marrow to concurrent chemoradiation for anal cancer.

Authors:  Maxwell Robinson; Rebecca Muirhead; Clare Jacobs; Rosie Cooke; Kwun-Ye Chu; Frank Van den Heuvel; Stasya Ng; Pradeep Virdee; Victoria Strauss; Maria Hawkins
Journal:  Radiother Oncol       Date:  2019-09-07       Impact factor: 6.280

9.  Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC).

Authors:  Jen Y Lee; Rosalind J Cutts; Ingrid White; Yolanda Augustin; Isaac Garcia-Murillas; Kerry Fenwick; Nik Matthews; Nicholas C Turner; Kevin Harrington; Duncan C Gilbert; Shreerang Bhide
Journal:  Front Oncol       Date:  2020-04-17       Impact factor: 5.738

10.  Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma.

Authors:  Emma Bluemke; Daniel Bulte; Ambre Bertrand; Ben George; Rosie Cooke; Kwun-Ye Chu; Lisa Durrant; Vicky Goh; Clare Jacobs; Stasya M Ng; Victoria Y Strauss; Maria A Hawkins; Rebecca Muirhead
Journal:  Clin Transl Radiat Oncol       Date:  2020-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.